Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting-Reference-Cited by-同舟云学术

Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting

Published:2017-06-14 Issue:8 Volume:20 Page:832-839
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Suzuki Cibele¹,Lopes da Silva Nilceia¹,Kumar Praveen²,Pathak Purnima²,Ong Siew Hwa³

Affiliation:

1. Novartis Biociências S.A., São Paulo, Brazil;

2. Novartis Healthcare Private Ltd, Hyderabad, India;

3. Novartis Pharma AG, Basel, Switzerland

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1333513

Reference39 articles.

1. The Global Asthma Report [Internet]. 2014. Auckland, New Zealand: The Global Asthma Network. http://www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdf. Accessed October 1, 2015

2. Prevention and control of diseases: chronic respiratory disease [Internet]. http://www.paho.org/bra/index2.php?option=com_content&do_pdf =1&id = 581. Accessed October 1, 2015

3. Asthma and the socio-economic reality in Brazil

4. Sistema de Informações de Mortalidade [Internet]. http://datasus.saude.gov.br/sistemas-e-aplicativos/eventos-v/sim-sistema-de-informacoes-de-mortalidade. Accessed August 13, 2015

5. Risk factors for death in patients with severe asthma

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic evaluation of biological treatments in patients with severe asthma: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-09

2. Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies;Journal of Asthma;2023-03-16

3. Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia;BMC Pulmonary Medicine;2022-11-28

4. Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence;Value in Health Regional Issues;2022-01

5. Direct cost analysis for patients with severe asthma receiving omalizumab treatment;Journal of Health Sciences and Medicine;2021-09-05